Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
06 2019
Historique:
received: 27 08 2018
revised: 20 12 2018
accepted: 18 01 2019
pubmed: 29 1 2019
medline: 14 4 2020
entrez: 29 1 2019
Statut: ppublish

Résumé

Combined hepatocellular-cholangiocarcinomas (CHC) are mixed tumours with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) components. CHC prognosis is similar to intrahepatic CC (ICC) and worse than HCC; staging and treatment generally follow ICC algorithms. However, the molecular biology of CHC remains poorly characterised. We performed capture-based next-generation sequencing of 20 CHC and, for comparison, 10 ICC arising in cirrhosis. Intratumour heterogeneity was assessed by separately sequencing the HCC and CC components of nine CHC. CHC demonstrated molecular profiles similar to HCC, even in the CC component. CHC harboured recurrent alterations in TERT (80%), TP53 (80%), cell cycle genes (40%; CCND1, CCNE1, CDKN2A), receptor tyrosine kinase/Ras/PI3-kinase pathway genes (55%; MET, ERBB2, KRAS, PTEN), chromatin regulators (20%; ARID1A, ARID2) and Wnt pathway genes (20%; CTNNB1, AXIN, APC). No CHC had alterations in IDH1, IDH2, FGFR2 or BAP1, genes typically mutated in ICC. TERT promoter mutations were consistently identified in both HCC and CC components, supporting TERT alteration as an early event in CHC evolution. TP53 mutations were present in both components in slightly over half the TP53-altered cases. By contrast, focal amplifications of CCND1, MET and ERRB2, as well as Wnt pathway alterations, were most often exclusive to one component, suggesting that these are late events in CHC evolution. ICC in cirrhosis demonstrated alterations similar to ICC in non-cirrhotic liver, including in IDH1 or IDH2 (30%), CDKN2A (40%), FGFR2 (20%), PBRM1 (20%), ARID1A (10%) and BAP1 (10%). TERT promoter and TP53 mutation were present in only one ICC each. Our data demonstrate that CHC genetics are distinct from ICC (even in cirrhosis) and similar to HCC, which has diagnostic utility and implications for treatment. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Identifiants

pubmed: 30690729
doi: 10.1002/path.5243
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

164-178

Informations de copyright

Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Auteurs

Nancy M Joseph (NM)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Christos G Tsokos (CG)

Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

Sarah E Umetsu (SE)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

A Hunter Shain (AH)

Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.

Robin K Kelley (RK)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.

Courtney Onodera (C)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Sarah Bowman (S)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Eric Talevich (E)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Linda D Ferrell (LD)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Sanjay Kakar (S)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Gregor Krings (G)

Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH